INS and Hypoglycemia: Moreover, females tended to have a higher risk of hypoglycemia than males when receiving TZD as the third antidiabetic agent (P value for interaction <0.05), although the increased risk of TZD compared to basal insulin in females was not significantly different (female HR 1.79 [95% CI 0.98–3.28] vs. male HR 0.71 [0.45–1.14]).